LENZ Therapeutics, Inc.

For the period ended Jun 30, 2025. Filed Jul 30, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Jul 30, 2025

LENZ$4.10-4.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except for shares and par value)

	June 30, 2025	December 31, 2024
(unaudited)
Assets
Current assets:
Cash and cash equivalents	$37,608	$20,158
Marketable securities	171,911	188,872
Prepaid expenses and other current assets	3,969	2,773
Restricted cash	114	114
Total current assets	213,602	211,917
Property and equipment, net	1,169	651
Operating lease right-of-use asset	959	1,338
Other assets	1,602	1,398
Total assets	$217,332	$215,304
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$2,854	$4,257
Accrued liabilities	7,544	6,149
Total current liabilities	10,398	10,406
Operating lease liability, net	569	814
Total liabilities	10,967	11,220
Commitments and contingencies (Note 6)
Stockholders' equity:
Common stock, par value of $0.00001 per share; 300,000,000 shares authorized; 28,501,715 and 27,531,490 shares issued at June 30, 2025 and December 31, 2024, respectively; and 28,500,122 and 27,518,439 shares outstanding at June 30, 2025 and December 31, 2024, respectively	1	1
Additional paid-in capital	380,871	348,901
Accumulated deficit	(174,545)	(145,014)
Accumulated other comprehensive income	38	196
Total stockholders’ equity	206,365	204,084
Total liabilities and stockholders’ equity	$217,332	$215,304

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.